Navigation Links
Velos, Inc. Launches 'Velos On-Demand' for Velos eResearch, Bringing Dynamically Scalable Economy to Customers
Date:7/9/2009

of Velos On-Demand can be initiated through a simple registration process. Services are supported by one of a number of support and training packages designed to move customers into production quickly and reliably.

Customers are enthusiastic with the resulting flexibility and speed. Henry J. Pollack, MD, Associate Professor, Department of Pediatrics, NYU, uses Velos On-Demand for clinical research being conducted in North and South America. "Within two weeks we had our forms up," stated Dr. Pollack. "With another system, it would have been months. I also credit the commitment of my staff as one of the elements that contributed to that speed."

About Velos

Velos is the trusted clinical trial management resource for investigators, sponsors and academic leaders throughout the U.S. The company serves 21 Top 25* U.S. medical centers. Velos eResearch is deployed for clinical research in all parts of the healthcare enterprise and supports a broad diversity of clinical departments and functional needs. The system fundamentally improves the way data is collected, organized and shared. A pure Internet technology platform, Velos eResearch harnesses advanced powers of the Internet to enable research sites, sponsors, and patients to participate in a secure, integrated system platform. System users are freed of redundant data entry and related time delays associated with most clinical research today. With emphasis on workflow, Velos integrates the clinical, administrative and financial information needs of research management. Velos eTools, a companion product to Velos eResearch, empowers customers by giving them ownership and access to functions such as system configuration, data migrations, custom reporting and third party data submissions. Founded in 1996, Velos is privately held with headquarters in Fremont, California. For more information, visit www.vel
'/>"/>

SOURCE Velos, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Velos, Inc. Appoints William Broucek Senior Director, Professional Services
2. Nursing Scrubs and Medical Scrubs Company blue sky scrubs Launches Enhanced Website
3. Autism Speaks Launches TV Ad Campaign Calling on Congress to End Insurance Discrimination Against Children with Autism
4. GetWellNetwork Continues Growth with Eleven New Hospital Launches and Contract Signings
5. Breakfast Anyone? Lifestyle Foods Launches Two Energizing Snacks Containing Under 200 Calories
6. Sokolove Law Launches Chinese Drywall Consumer Advocacy Hotline
7. Perot Systems Launches Website in Chinese to Support Expansion Into China
8. CareFusion Corporation Launches International Jazz Festival Series
9. ERT Launches New Online Gateway to Improve Cardiac Safety in Clinical Trials
10. LifeNet Health Launches Sports Medicine Bio-Implants
11. Premier Research Launches Oracle(R) Remote Data Capture Onsite 4.5.3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... free of blood and protein soils where it ... Miele, the world’s leading manufacturer of premium domestic ... to verifying surgical instruments are effectively cleaned. The ... of surgical instruments immediately after processing. After 3 ...
(Date:7/29/2014)... is in principle suitable to find out which preferences ... it in health economic evaluations, some (primarily methodological) issues ... of a pilot project by the German Institute for ... Analytic Hierarchy Process (AHP), CA is the second method ... Summarize outcome-specific results to an overall value ...
(Date:7/29/2014)... new lung is grown for a patient in need, using ... injection of replacement cells will enable a patient to self-heal ... ALERT: For audio and video of Dr. Keller and Jorge ... Mayo Clinic News Network . , Regenerative ... gift from Jorge and Leslie Bacardi of the Bahamas will ...
(Date:7/29/2014)... Foot Levelers Chairman and CEO Kent S. Greenawalt ... (FCA) National Convention and Expo, speaking on Ground Force ... on Thursday, August 20th at the Hyatt Regency in ... impact functional foot orthotics, like Foot Levelers Stabilizing Orthotics, ... fasciitis, and hammertoes. , Invented by a chiropractor in ...
(Date:7/29/2014)... July 29, 2014 1WorldSync announces ... leading healthcare suppliers will utilize the Global Data ... information network to share product information with the ... trading partners across their global supply chain. Holger ... at B. Braun: "B. Braun serves customers in ...
Breaking Medicine News(10 mins):Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3
... say the drug clodronate is an effective treatment for patients ... studied more than 1,000 patients // with breast cancer. Patients ... day or a placebo for five years. ,Results showed ... to their bones. Fifty-one of these patients were treated with ...
... identified a protein that essentially blocks HIV replication, in ... is not as effective at stopping HIV, say the ... of Nature. The team, headed by Joseph Sodroski, is ... Infectious Diseases (NIAID). ,"Identification of this HIV-blocking ...
... According to recent findings researchers say the risks and ... to be re-evaluated.// Researchers from Sweden studied more than ... of age. Participants had their intellectual capacity tested at ... school attendance records for the young men. ,Results ...
... pressure at home may lead to fewer blood pressure ... at patients’ homes to conventional doctors’ office measurements of ... patients with a diastolic blood pressure reading of 95 ... offices were included for the study. All of the ...
... a new treatment can now help chronic chest pain sufferers ... other antianginal medications it was found to improve the total ... ,Ranolazine is currently under review by the FDA. ... angina were randomly assigned to receive a placebo or one ...
... a non-surgical technique used to eliminate alternate pathways ... // Researchers now say that congestive heart failure ... of irregular heart rhythm experience significant improvement ... catheter ablation. ,58 patients with congestive heart ...
Cached Medicine News:
(Date:7/29/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.476 ... or $(0.02) per share. These results compare to net ... $311 thousand, or $(0.04) per share, in the year-ago ...
(Date:7/28/2014)... , July 28, 2014 Pharmacyclics, Inc. (the "Company") ... hold a conference call and audio webcast to discuss financial ... Market closes on Thursday, July 31, 2014 at 4:30 p.m. ... Date: July 31, 2014 Time: 4:30 PM ... 303-7908 International: (678) 373-0875 A webcast replay will ...
(Date:7/28/2014)...  MiMedx Group, Inc. (NASDAQ: MDXG ), an integrated ... bioimplants processed from human amniotic membrane, announced today its results ... include: , Revenue exceeds upper end of ... million , Quarter-over-quarter revenue grew by ... 181% over Q2 2013 and 40% sequentially over Q1 2014 ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2015 Results 2Encision Reports First Quarter Fiscal Year 2015 Results 3Encision Reports First Quarter Fiscal Year 2015 Results 4Pharmacyclics Announces Date of Conference call to discuss Financial Results for Second Quarter of 2014 2MiMedx Announces Record Second Quarter Results 2MiMedx Announces Record Second Quarter Results 3MiMedx Announces Record Second Quarter Results 4MiMedx Announces Record Second Quarter Results 5MiMedx Announces Record Second Quarter Results 6MiMedx Announces Record Second Quarter Results 7MiMedx Announces Record Second Quarter Results 8MiMedx Announces Record Second Quarter Results 9MiMedx Announces Record Second Quarter Results 10MiMedx Announces Record Second Quarter Results 11MiMedx Announces Record Second Quarter Results 12MiMedx Announces Record Second Quarter Results 13MiMedx Announces Record Second Quarter Results 14MiMedx Announces Record Second Quarter Results 15MiMedx Announces Record Second Quarter Results 16MiMedx Announces Record Second Quarter Results 17MiMedx Announces Record Second Quarter Results 18
... Phase II Trial Initiated by Myriad For Azixa(TM), ... and OMX Nordic Exchange: EPCT) today reported on ... agent,licensed by the Company to Myriad Genetics, Inc. ... agreement. (Logo: http://www.newscom.com/cgi-bin/prnh/20020513/NYM112LOGO ) ...
... DNDN ) today announced publication of results ... active cellular immunotherapy, in the,August 20 issue of ... safety profile, immune response and clinical activity of ... failed standard,therapy. "In addition to demonstrating that ...
Cached Medicine Technology:EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 2EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 3EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 4EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound 5Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 2Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 3Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients 4
... The new Guidant VASOVIEW® ... to deliver a new level ... harvesting for both the saphenous ... simultaneous cut-and-seal capability, it lets ...
...
... Now rapid intrapartum or antepartum GBS results ... versus 2 days. This revolutionary in vitro diagnostic ... designed to be run in the clinical lab ... and delivery nurses 24 hours a day, ...
... contains primers and a FAM-labeled probe that is ... the mecA gene. In addition, this ASR contains ... an internal control sequence. This ASR requires an ... reporter dyes such as the Cepheid SmartCycler System. ...
Medicine Products: